Dissolving Candlelit Microneedle for Chronic Inflammatory Skin Diseases

• Main Authors: Jungyoon Ohn, Mingyu Jang, Bo Mi Kang, Huisuk Yang, Jin Tae Hong, Kyu Han Kim, Ohsang Kwon, Hyungil Jung
• Format: Article
• Language: English
• Published: Wiley 2021-07-01
• Series: Advanced Science
• Subjects: candlelit microneedles; chronic inflammatory skin diseases; dissolving microneedles; triamcinolone acetonide
• Online Access: https://doi.org/10.1002/advs.202004873

Abstract Chronic inflammatory skin diseases (CISDs) negatively impact a large number of patients. Injection of triamcinolone acetonide (TA), an anti‐inflammatory steroid drug, directly into the dermis of diseased skin using needle‐syringe systems is a long‐established procedure for treating recalcitrant lichenified lesions of CISDs, referred to as TA intralesional injection (TAILI). However, TAILI causes severe pain, causing patients to be stressed and reluctant to undergo treatment. Furthermore, the practitioner dependency on the amount and depth of the injected TA makes it difficult to predict the prognosis. Here, candle flame (“candlelit”)‐shaped TA‐loaded dissolving microneedles (Candlelit‐DMN) are designed and fabricated out of biocompatible and biodegradable molecules. Candlelit‐DMN distributes TA evenly across human skin tissue. Conjoined with the applicator, Candlelit‐DMN is efficiently inserted into human skin in a standardized manner, enabling TA to be delivered within the target layer. In an in vivo skin inflammation mouse model, Candlelit‐DMN inserted with the applicator effectively alleviates inflammation by suppressing inflammatory cell infiltration and cytokine gene expression, to the same extent as TAILI. This Candlelit‐DMN with the applicator arouses the interest of dermatologists, who prefer it to the current TAILI procedure.